The U.S. Senate passed a revised Biosecure Act as an amendment to the National Defense Authorization Act, advancing language that would restrict federal funding and contracting with biotechnology firms of concern. The amendment stops short of naming specific Chinese firms but expands oversight and procurement limits tied to national security lists. Legislators embedded the measure into the defense spending bill to increase its chances of enactment, setting up a conference with the House where versions differ. Industry stakeholders and research institutions warned the move could affect international supply chains, contract manufacturing access and collaborations, while proponents framed it as a national security step to prevent adversarial access to critical biotech capabilities.